Systemic sclerosis is an autoimmune connective tissue disease, which is characterised by
immune dysregulation and progressive fibrosis that typically affects the skin, with variable …

Background Approximately one‐third of individuals with interstitial lung disease (ILD) have
associated connective tissue disease (CTD). The connective tissue disorders most …

Allogeneic chimeric antigen receptor (CAR)-T cells hold great promise for expanding the
accessibility of CAR-T therapy, whereas the risks of allograft rejection have hampered its …

Background: This document provides clinical recommendations for the diagnosis of
idiopathic pulmonary fibrosis (IPF). It represents a collaborative effort between the American …

The aim was to update the 2009 European League against Rheumatism (EULAR)
recommendations for the treatment of systemic sclerosis (SSc), with attention to new …

Background 12 months of oral cyclophosphamide has been shown to alter the progression
of scleroderma-related interstitial lung disease when compared with placebo. However …

Objectives SSc is characterized by fibrotic changes in the skin and lung, and the mainstay of
treatment has been CYC. B cell involvement suggests that rituximab (RTX) may also be of …

Objective To assess survival and identify predictors of survival in patients with systemic
sclerosis-interstitial lung disease (SSc-ILD) who participated in the Scleroderma Lung …

Idiopathic pulmonary fibrosis (IPF) and systemic sclerosis-associated interstitial lung
disease (SSc-ILD) differ in the predominant demographics and identified genetic risk alleles …

The Biomarkers Definitions Working Group defines a clinical endpoint as a variable that
reflects how a patient feels, functions, or survives (5, 6). The past 3 decades of IPF clinical …